PRINCETON, N.J., Dec. 15 /PRNewswire-FirstCall/ -- Covance Inc. today announced the opening of new clinical development offices in Seoul, South Korea and Mumbai, India and office expansions in Tokyo, Japan and Hong Kong, China to accommodate growing demand for clinical development services in Asia-Pacific.
The new clinical development office in Seoul will help Covance further increase patient access in the region, while supporting its regional network of field-based CRAs throughout Asia-Pacific. The new Mumbai office will function as the main clinical trial support hub for the Indian sub-continent.
"Our new Asia-Pacific offices support our global expansion strategy, which targets the most qualified investigators and appropriate patient populations in a region that is increasingly important to clinical trials," said Nick Wright, vice president and general manager, clinical development services Asia-Pacific, Covance. "These offices will help us increase our clients' Phase II/III clinical trial productivity by providing additional capacity to execute clinical studies with a full range of services."
Covance offers clinical development services in 55 countries, including emerging markets across Asia-Pacific, Central and Eastern Europe, and Latin America. With a full suite of services to take a drug through all stages of development, Covance offers extensive clinical and therapeutic expertise, global reach, proactive project management, and strong investigator site relationships to consistently deliver high quality data on time.
Statements contained in this press release, which are not historical facts, are forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All such forward-looking statements including the statements contained herein regarding anticipated trends in the Company's business are based largely on management's expectations and are subject to and qualified by risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, without limitation, competitive factors, outsourcing trends in the pharmaceutical industry, levels of industry research and development spending, the Company's ability to continue to attract and retain qualified personnel, the fixed price nature of contracts or the loss of large contracts, and other factors described in the Company's filings with the Securities and Exchange Commission.
www.covance.com
CONTACT: Media Relations for Covance Inc., +1-609-419-2466, or Investor
Relations for Covance Inc., +1-609-452-4807
Web site: http://www.covance.com/
